Cardiac Sarcoidosis
1
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Rhine PharmaGermany - Heidelberg
1 programBiomaterial Collection - and Analysis in Cardiac SarcoidosisN/A1 trial
Active Trials
Berlin HeartTX - The Woodlands
1 programBiomaterial Collection - and Analysis in Cardiac SarcoidosisN/A
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
2029
Prevail TherapeuticsBaricitinib
Rhine PharmaBiomaterial Collection - and Analysis in Cardiac Sarcoidosis
Clinical Trials (2)
Total enrollment: 110 patients across 2 trials
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Start: Apr 2026Est. completion: Dec 202810 patients
Phase 2Not Yet Recruiting
Biomaterial Collection - and Analysis in Cardiac Sarcoidosis
Start: Apr 2023Est. completion: Apr 2029100 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.